Status:
COMPLETED
Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study
Lead Sponsor:
Fondazione del Piemonte per l'Oncologia
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
The MET oncogene is known to sustain the Trousseau's syndrome in murine experimental models, featuring association of carcinogenesis with a blood procoagulant disorder. MET is frequently overexpressed...
Eligibility Criteria
Inclusion
- age \> or = 18;
- age \< or = 80;
- Clinical diagnosis of colorectal tumor by CT, MRI or endoscopy;
- surgically resectable tumor;
Exclusion
- Inclusion in other clinical protocols requiring administration of anticoagulant drugs;
- Life expectancy \< 6 month;
- Clinical diagnosis of thrombophilic condition by laboratory analysis;
- Previously implanted Central Venous Catheter;
- Previous or concomitant second neoplasia;
- Clinical diagnosis of kidney, liver or heart failure;
- Inflammatory markers alteration associated with disease unrelated to neoplasia (infection, connective tissue disease etc);
- Severe hemostasis disorder;
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02238821
Start Date
October 1 2007
End Date
December 1 2016
Last Update
March 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione del Piemonte per l'Oncologia
Candiolo, TO, Italy, 10060